Key Highlights

  • Shares were down 12.43% to USD 4.51 in pre-market trading on November 4, 2026.
  • The implied Tuesday close was about USD 5.15 (calculated), so the drop equals USD 0.6402.
  • A 1-for-10 reverse split took effect on June 11, 2026.
  • A public offering announced March 6, 2026 raised about USD 3.5 million gross through 7.0 million shares and pre-funded warrants (calculated total).
  • A private Placement announced November 3, 2025 raised USD 2.5 million at an effective USD 4.00 per share.

What Moved Shuttle Pharmaceuticals Before the Open (down USD 0.6402, 12.43%)

Shuttle Pharmaceuticals (NASDAQ:SHPH) was down 12.43% to USD 4.51 in pre-market trading on November 4, 2026, compared with the Tuesday November 3, 2026 close. The screen figures imply a prior close of about USD 5.15 (calculated), so the stock is giving back a visible slice of recent strength.

No company press release, Earnings report or regulatory filing dated November 2, 3 or 4, 2026 was identified. The move therefore looks like trading driven by a small share base and a thin order book, which is an inference and not a confirmed cause.

The Capital Raises Behind the Share Count

According to a company press release dated March 6, 2026, Shuttle sold 2,238,800 shares and pre-funded warrants for 4,761,200 shares in a public offering with gross proceeds of about USD 3.5 million, implying roughly USD 0.50 per share before the later reverse split (calculated). Up to USD 1.5 million of net proceeds was earmarked for marketing, with the rest for Working Capital and general corporate purposes.

Adjusted for the 1-for-10 reverse split, that price equals roughly USD 5.00 per share (calculated), close to where the stock trades now. Earlier, on November 3, 2025, the company announced a USD 2.5 million private placement at an effective USD 4.00 per share.

Business Background and Recent Updates

Shuttle Pharmaceuticals Holdings is a Gaithersburg, Maryland company that has developed cancer therapy candidates aimed at improving radiation treatment outcomes. On November 21, 2025, it announced the Acquisition of an AI health platform, widening its focus beyond traditional drug development.

Stockholders at the annual meeting on May 21, 2026 approved board discretion for a reverse split ranging from 1-for-2 to 1-for-150. The board chose 1-for-10 on June 1, 2026, and a regulatory filing showed trading on a split-adjusted basis began June 11, 2026, with warrants and convertible preferred stock adjusted proportionally. That filing was signed by an interim co-chief executive officer.

Balance Sheet and Risks

Detailed cash and Debt figures for the most recent quarter were not confirmed in the sources reviewed, so none are cited here. The pattern of repeated small Equity raises, pre-funded warrants and a reverse split points to ongoing funding needs and a risk of further dilution.

At under USD 5 per share, the stock is a penny stock, and shares in this category can be volatile, thinly traded and prone to sharp reversals. Warrant exercises and new offerings could add to the share count and pressure the price.

What to Watch Next

Investors will look for the company's Quarterly Report for the period ended September 30, 2026, which should update cash, spending and any progress on the AI health platform. Any new offering, warrant inducement or Nasdaq correspondence would also matter.

Management commentary on strategy and leadership, including the interim co-chief executive structure, is another item to follow. Trading Volume once regular hours open on November 4, 2026 will show whether the pre-market decline holds.